These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 35606821)

  • 61. Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells.
    Koristka S; Ziller-Walter P; Bergmann R; Arndt C; Feldmann A; Kegler A; Cartellieri M; Ehninger A; Ehninger G; Bornhäuser M; Bachmann MP
    Cancer Immunol Immunother; 2019 Sep; 68(9):1401-1415. PubMed ID: 31414180
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection.
    Hu W; Huang X; Huang X; Chen W; Hao L; Chen Z
    Biomed Pharmacother; 2019 Oct; 118():109333. PubMed ID: 31545280
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Exhaustion, rather than lack of infiltration and persistence, of CAR-T cells hampers the efficacy of CAR-T therapy in an orthotopic PDAC xenograft model.
    Takeuchi Y; Wang Y; Sasaki K; Sato O; Tsuchikawa T; Wang L; Amaishi Y; Okamoto S; Mineno J; Hirokawa Y; Hatanaka KC; Hatanaka Y; Kato T; Shiku H; Hirano S
    Biomed Pharmacother; 2024 Jan; 170():116052. PubMed ID: 38141280
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Challenges and optimal strategies of CAR T therapy for hematological malignancies.
    Zhang Y; Xu Y; Dang X; Zhu Z; Qian W; Liang A; Han W
    Chin Med J (Engl); 2023 Feb; 136(3):269-279. PubMed ID: 36848181
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy.
    Harrer DC; Dörrie J; Schaft N
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768665
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.
    Zhao J; Wu M; Li Z; Su S; Wen Y; Zhang L; Li Y
    Ann Hematol; 2020 Aug; 99(8):1681-1699. PubMed ID: 32388608
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
    Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
    J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
    Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
    Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice.
    Wudhikarn K; Park JH
    Leuk Lymphoma; 2020 Oct; 61(10):2324-2334. PubMed ID: 32522059
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon.
    Martino M; Naso V; Loteta B; Canale FA; Pugliese M; Alati C; Musuraca G; Nappi D; Gaimari A; Nicolini F; Mazza M; Bravaccini S; Derudas D; Martinelli G; Cerchione C
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362130
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
    Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
    Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Chimeric Antigen Receptor T Cells for B-Cell Lymphoma.
    Newcomb R; Jacobson C
    Cancer J; 2021 Mar-Apr 01; 27(2):107-111. PubMed ID: 33750069
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells.
    Zhu X; Hu H; Xiao Y; Li Q; Zhong Z; Yang J; Zou P; Cao Y; Meng F; Li W; You Y; Guo AY; Zhu X
    Cancer Lett; 2022 Jun; 536():215668. PubMed ID: 35367518
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry.
    Maryamchik E; Gallagher KME; Preffer FI; Kadauke S; Maus MV
    Cytometry B Clin Cytom; 2020 Jul; 98(4):299-327. PubMed ID: 32352629
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.
    Bell M; Gottschalk S
    Front Immunol; 2021; 12():684642. PubMed ID: 34177932
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Chimeric Antigen Receptor T-cells (CARs) in Cancer Treatment.
    Zam W; Assaad A
    Curr Mol Pharmacol; 2022; 15(3):532-546. PubMed ID: 34382510
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Application and Design of Switches Used in CAR.
    Głowacki P; Rieske P
    Cells; 2022 Jun; 11(12):. PubMed ID: 35741039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.